Four significant promoter stake sales through block deals in September 2026 attracted marquee institutional investors including DSP Mutual Fund, Kotak Mahindra Mutual Fund, ICICI Prudential AMC, and Capital Group's Smallcap World Fund. According to reports from The Financial Express, these transactions occurred as all three companies reported strong quarterly numbers with visible improvement in revenue, profitability, and business mix. The timing of these deals suggests institutions were not merely providing liquidity to large sellers but actively building positions in businesses where fundamentals are starting to look better.
On September 11th, promoters Pradeep Singh Jauhar and Randeep Singh Jauhar sold a 5% stake at ₹128 per share, with shares bought by DSP Mutual Fund, 360 ONE Asset Management, and Abu Dhabi Investment Authority. As reported by The Financial Express, Jamna Auto's Q1FY27 revenue increased 7% YoY to ₹612 crore, while EBITDA grew 12.8% to ₹88 crore with margins expanding to 14.4%. The company is targeting ₹5,000 crore revenue by FY30, representing a significantly faster growth trajectory than its historical 4% CAGR between FY23-FY26.
On September 4th, Chinese promoter Fosun Pharma sold a 6% stake worth ₹2,800 crore, with Kotak Mutual Fund being the single biggest buyer at ₹790 crore. According to The Financial Express, Gland Pharma's Q1FY27 revenue from operations rose 19.6% YoY to ₹1,800 crore, while net profit jumped 47.9% to ₹317 crore with EBITDA margins expanding 300 bps to 27.4%. The company is gradually moving beyond traditional injectables towards higher-entry-barrier CDMO opportunities, with the CDMO business contributing nearly 50% of sales.
On September 11th, Chairman Krishna Prasad Chigirupati sold a 7% stake for ₹1,509 crore as the stock was trading close to a decade high. As reported by The Financial Express, Granules India reported its strongest quarter on record with Q1FY27 revenue increasing 22% YoY to ₹1,477 crore and net profit jumping 59.3% to ₹180 crore. The company's complex generics business now accounts for 50% of finished-dosage revenue, up from 39% a year earlier, while net debt fell to ₹101 crore during the quarter.
Groww shares fell nearly 3% on Wednesday following a large block deal involving around ₹1,999 crore worth of shares. According to TradingView News, approximately 10.41 crore shares representing 1.69% of the company's equity were transacted at ₹192 per share. At the end of June, promoter entities held 27.14% of Billionbrains Garage Ventures, while public shareholders owned 71.75%. The selling pressure comes despite positive analyst coverage, with Jefferies maintaining a Buy rating and target price of ₹240, expecting 30% CAGR in profit after tax between FY26-FY29.
